Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors

A Phase 1 Study Of AG-013736 (Axitinib) In Japanese Patients With Advanced Solid Tumors

To evaluate the clinically recommended dose of AG-013736 (Axitinib) in Japanese patients by reviewing the safety of AG-013736 (Axitinib) following single and multiple dosing.

Inclusion Criteria:

• Patients histologically or cytologically diagnosed with advanced malignant solid tumors
• Patients for whom standard therapies have not been effective, or for whom there are no suitable therapies

Exclusion Criteria:

• Central lung lesions involving major blood vessels
• Patients who have been treated with bevacizumab or other VEGFR inhibitor(s)